2375835-91-7

2375835-91-7 structure

Name: Lusvertikimab
Chemical Name: Lusvertikimab
CAS Number: 2375835-91-7
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
Create Date: 2023-04-05 15:47:12
Modify Date: 2024-01-14 13:11:30
Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1].

Name	Lusvertikimab

Description	Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> Interleukin Related
Target	IL7R
In Vitro	OSE-127 (4 天) 可阻断 IL7 依赖性 ALL 细胞系和患者来源的异种移植 (PDX) 样本中的 STAT5 磷酸化[2]。
In Vivo	当相应的对照小鼠显示出明显白血病的临床症状时，OSE-127 处理的小鼠体内 21/22 (95%) PDX 样本显示外周血 (PB) 母细胞减少[1]。
References	[1]. Lennart Lenk, et al. The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action. ACUTE LYMPHOBLASTIC LEUKEMIAS: BIOMARKERS, MOLECULAR MARKERS AND MINIMAL RESIDUAL DISEASE IN DIAGNOSIS AND PROGNOSIS\| NOVEMBER 15, 2022. [2]. Elodie Rivière,, et al. Interleukin-7/Interferon Axis Drives T Cell and Salivary Gland Epithelial Cell Interactions in Sjögren's Syndrome. Arthritis Rheumatol. 2021 Apr;73(4):631-640.

No Any Chemical & Physical Properties